To the Editor: The critical review on cancer surveillance in ulcerative colitis (June 25 issue)1 is an excellent summary of current knowledge. However, patients and physicians are left with a problem: Should those at high risk for cancer be screened for dysplasia? Analyses of findings from patients enrolled in our surveillance program indicate that screening provides certain benefits that should be offered to high-risk patients. The University of Chicago surveillance program has existed for 10 years and has enrolled 99 patients who had pancolitis for an average of 17 years at the time of entry. In addition to the extent.
ASJC Scopus subject areas